ADDF-Harrington
Forecasted
ADDF-Harrington supports academic investigators with research funding and drug development expertise to advance medicines for Alzheimer’s disease, related dementias, and aging-related cognitive decline.
Funder: Harrington Discovery Institute
Due Dates (Anticipated): June 2027 (LOI) | August 2027 (Full application)
Funding Amounts: Up to $600,000 over two years, plus drug development support; up to two scholars annually
Summary: Supports academic investigators developing therapeutics for Alzheimer’s disease, related dementias, and cognitive decline associated with aging.
Key Information: Funding uses mission-related investments requiring return on investment based on scientific and/or business milestones.
Description
ADDF-Harrington is a joint initiative of the Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute’s Brain Health Medicines Centers. It advances academic discoveries into medicines that treat, prevent, slow, or reverse Alzheimer’s disease and related dementias. The program seeks innovative discoveries addressing unmet medical needs, with potential for clinical impact, commercial development, and strong intellectual property protection.
Awards combine research funding with a personalized team of pharmaceutical industry experts and a project manager. Support includes medicinal chemistry, pharmacology, toxicology, business and commercialization advice, clinical development, regulatory assistance, IP review, and help securing additional financial support. The program supports novel small molecules, antibodies, peptides, oligonucleotides, gene therapies, and other therapeutic modalities. Diagnostics and devices must be part of a therapeutic development project.
